HUNTER SYNDROME (TYPE II MUCOPOLYSACCHARIDOSIS). KEYS FOR ITS RECOGNITION AND DIAGNOSIS

被引:0
|
作者
Andres, A. G. Andres [1 ]
机构
[1] Complejo Asistencial Univ Leon, Serv Pediat, Leon, Spain
来源
BOLETIN DE PEDIATRIA | 2024年 / 64卷 / 267期
关键词
Mucopolysaccharidosis (MPS); Hunter's syndrome (SH); Enzyme replacement therapy; ENZYME REPLACEMENT THERAPY;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Mucopolysaccharidosis (MPS) is a group of metabolic hereditary disorders included in the lysosomal diseases. They are genetic diseases caused by the defects in intralysosomal enzymes necessary for the processing of Glycosaminoglycans. (GAG). The defect in the degradation of these macromolecules causes accumulation in the cells of different organs with irreversible and progressive lesions when we don ' t treat them(1). The mucopolysaccharidosis II (MPS II) or Hunter's Syndrome (EH) is caused by the absence or decrease of the enzyme iduronute-2-sulfatase (I2S), with the consequent blockage in the degradation of glycosaminoglycans, dermatan-sulfate and heparan sulfate, in cytoplasmic lysosomes, which accumulate in different tissues causing disabling progressive and multisystemic affectation(1). Pediatricians and other specialists, who treat children, must know to recognize those symptoms or signs of alarm and they must refer these patients to specialized units, and make early and accurate diagnoses to stop their physical and neurological deterioration. In the last years, specific treatments for the disease, enzyme replacement therapy, and stem cell transplantation have helped address the underlying enzyme deficiency in patients with MPS II. However, the multisystemic nature of this disorder and the irreversibility of some manifestations mean that most patients require constant support from many specialties.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
    Mireia Raluy-Callado
    Wen-Hung Chen
    David A H Whiteman
    Juanzhi Fang
    Ingela Wiklund
    [J]. Orphanet Journal of Rare Diseases, 8
  • [42] Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
    Whiteman, David A. H.
    Kimura, Alan
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2467 - 2480
  • [43] The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
    Raluy-Callado, Mireia
    Chen, Wen-Hung
    Whiteman, David A. H.
    Fang, Juanzhi
    Wiklund, Ingela
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [44] Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey
    Mendelsohn, Nancy J.
    Harmatz, Paul
    Bodamer, Olaf
    Burton, Barbara K.
    Giugliani, Roberto
    Jones, Simon A.
    Lampe, Christina
    Malm, Gunilla
    Steiner, Robert D.
    Parini, Rossella
    [J]. GENETICS IN MEDICINE, 2010, 12 (12) : 816 - 822
  • [45] Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line
    Altarescu, Gheona
    Renbaum, Paul
    Eldar-Geva, Talia
    Brooks, Baruch
    Varshaver, Irit
    Avitzour, Mical
    Margalioth, Ehud J.
    Levy-Lahad, Ephrat
    Elstein, Deborah
    Epsztejn-Litman, Silvina
    Eiges, Rachel
    [J]. PRENATAL DIAGNOSIS, 2011, 31 (09) : 853 - 860
  • [46] Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II)
    Braun, SE
    Pan, D
    Aronovich, EL
    Jonsson, JJ
    McIvor, RS
    Whitley, CB
    [J]. HUMAN GENE THERAPY, 1996, 7 (03) : 283 - 290
  • [47] Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review
    Bradley, Linda A.
    Haddow, Hamish R. M.
    Palomaki, Glenn E.
    [J]. GENETICS IN MEDICINE, 2017, 19 (11) : 1187 - 1201
  • [48] Multimodal image analysis of the retina in Hunter syndrome (mucopolysaccharidosis type II): Case report
    Macedo Salvucci, Isadora Darriba
    Finzi, Simone
    Oyamada, Maria Kiyoko
    Kim, Chong Ae
    Gianotti Pimentel, Sergio Luis
    [J]. OPHTHALMIC GENETICS, 2018, 39 (01) : 103 - 107
  • [49] ENZYME REPLACEMENT THERAPY (ERT)RESULTS OF PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME)
    Unal, O.
    Dogru-Ersoz, D.
    Alehan, D.
    Saglam, M.
    Hismi, B.
    Dursun, A.
    Tokatli, A.
    Coskun, T.
    Sivri, H. S.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S145 - S145
  • [50] ANESTHETIC MANAGEMENT IN MUCOPOLYSACCHARIDOSIS TYPE 2 (HUNTER SYNDROME, MPS II): CASE REPORT
    Caparlar, Ceyda Ozhan
    Sezer, Evginar
    [J]. PEDIATRIC NEPHROLOGY, 2018, 33 (10) : 1948 - 1948